Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 8Anemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 7Myelodysplastic Syndromes 7Primary Myelofibrosis 5Myeloproliferative Disorders 5Lymphoma, Follicular 5Leukemia 5Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 5Thrombocytopenia 4Polycythemia Vera 4Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Lymphocytic, Chronic, B-Cell 4Febrile Neutropenia 4Congenital Abnormalities 4Anemia, Sickle Cell 4Anemia, Aplastic 4Thrombocythemia, Essential 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Neutrophilic, Chronic 3Leukemia, Myelomonocytic, Chronic 3Burkitt Lymphoma 3Blast Crisis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Arthritis, Juvenile × Classical hematology × Clear all
NCT01206907 2012-08-17

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects

Endo Pharmaceuticals

Phase 3 Withdrawn
Classical hematology

Anemia, Sickle Cell, Arthritis, Juvenile, Neoplasms, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡